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he Elusive Scourge
f Sudden Cardiac Death
s Rational Decision Making Possible?
hould There Be Standards
f Risks and Predictions in Medicine?*
aved Butler, MD, MPH, FACC,
ngel Leon, MD, FACC
tlanta, Georgia
mong the many intriguing aspects of heart failure (HF),
rguably none is more elusive than predicting sudden cardiac
eath (SCD). Despite availability of validated risk scores for
ll-cause mortality prediction for these patients (e.g., the Heart
ailure Survival Score and the Seattle Heart Failure Model),
here are no such guidelines for predicting SCD (1,2).Multiple
lectrocardiographic patterns have been correlated with risk of
CD; however, none seem sensitive and specific enough to
uide therapy solely on the basis of their results. Initial trials
ssessing therapy for SCD have used very specific enrollment
riteria (i.e., history of SCD survival [with very low sensitivity
nd as secondary prevention therapy]) or cumbersome
riteria such as a need for inducing ventricular tachycar-
ia during electrophysiology study (3). Despite the vigor
f this latter approach, electrophysiological study-guided
herapy was not adopted widely for primary prevention
urposes because the follow-up of patients who were not
nducible for arrhythmia (and therefore inaccurately
hought to be safe) showed the same risk of death as
hose patients who refused to participate in the trial and
ere followed up in a registry.
See page 1427
Based on these experiences, the MADIT-II (Multicenter
utomatic Defibrillator Implantation Trial II) study enrolled
atients with ischemic cardiomyopathy and an ejection fraction
f30% and randomly assigned them to receive a defibrillator
r standard care (4). The rationale for this approach was sound;
hese patients are at high risk for SCD that cannot be predicted
ccurately. This trial was positive for a 9% absolute reduction in
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.b
From Emory University, Atlanta, Georgia. Dr. Leon has received research support
rom and has been a consultant to Medtronic, Inc. and Guidant, Inc.ll-cause mortality at 3 years. This was followed by the
CD-HeFT (Sudden Cardiac Death in Heart Failure Trial)
tudy, which showed a 7.5% reduction in all-cause mortality at
years with a defibrillator (5). This trial included both
schemic and nonischemic patients with an ejection fraction of
36%. The results of these 2 studies swung medical practice
rom using defibrillators according to least sensitive secondary
revention criteria (i.e., survivors of SCD) to least specific
rimary prevention criteria: a defibrillator for all with a low
jection fraction.
Which end of the spectrum is appropriate is a matter of
ebate. Clearly waiting for syncope or SCD as an eligibility
riterion is too restrictive, because patients may not survive the
nitial arrhythmic episode. But should everyone with heart
ailure and moderate systolic dysfunction get a defibrillator?
roponents would argue that liberal indications give patients
he best result. One should be careful in phrasing this assertion;
defibrillator for all gives the patients on average the best result.
pponents would argue that the costs to society are not
ustifiable, because many patients will not benefit from a
efibrillator. They will either never have ventricular arrhyth-
ias, or if they do, not all defibrillator shocks will be able to
ustain life for these failing ventricles, or the defibrillators will
o nothing to address comorbid conditions leading to death.
hus, at both ends of the disease spectrum, the benefit may be
arginal. In addition to the costs and futility are issues related
o procedure complications, and more importantly, the unan-
wered questions regarding quality of life with defibrillators in
egard to end-of-life issues.
The search for high-risk category patients who are likely to
enefit the most from a defibrillator has been slow for multiple
easons. Predicting SCD can be difficult. There exists a
isincentive for physicians, hospitals, and industry to narrow
he indications. This is partly because of the monetary incen-
ive, but also because of the fear of malpractice risk if a patient
ith heart failure dies suddenly without a defibrillator. The
ombination of financial incentives and fear of litigation have a
ervasive effect across medical practice.
In an environment of everything for all, the study by
oldenberg et al. (6) in this issue of the Journal provides
urther evidence that a defibrillator does not help all heart
ailure patients. In this secondary analysis of the MADIT-II
atabase, the investigators show that patients with preserved
ystolic blood pressure benefit little, if at all, from a
efibrillator. Whether this represents a special pathophysi-
logical relationship between blood pressure and risk of
CD, or simply that preserved blood pressure is a marker of
ealthier patient overall, can be debated. These results
bviously must be taken with caution. This is only one
tudy, this was a secondary analysis with limited power on
ata not collected specifically to answer this question, and
he patient population was restricted to the enrollment
riteria of MADIT-II study. Therefore, the results need to
e validated by other studies in a wider patient population.
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April 3, 2007:1434–5 Editorial Commentowever, this study reinforces the need for research to
mprove rational medical decision making.
Ideally the initial study designs for MADIT-II and
CD-HeFT should have randomly assigned patients strat-
fied by ejection fraction ranges or other important heart
ailure risk predictors. Moreover the impact of comorbidi-
ies should have been taken into account up front. However,
he increase in the number of patients needed to achieve
tatistical power with this approach would have increased
he cost to the study sponsor. The easiest and cheapest way
as to cast wider nets. However, we may have answered
ome very important questions prospectively, instead being
eft to tease answers to important clinical questions by
etrospective and less-than-optimal analyses.
Let us return to the original problem: why do we have
rediction models for all-cause mortality but not for SCD? Is
he prediction of SCD so different from all-cause mortality?
he answer may have more to do with our risk tolerance than
isk assessment per se. The c-statistics for all-cause mortality (a
easure to describe the variability in outcome explained by the
rediction rule) in the derivation data sets for the Heart Failure
urvival Score and the Seattle Heart Failure Model were 0.74
nd 0.72, respectively. In other words, more than one-quarter
f the outcome variability could not be explained by either
odel. Yet these models are accepted and used in medical
ractice routinely (e.g., in transplant listings). Why is it that
his degree of uncertainty is acceptable by the medical com-
unity for all-cause mortality prediction? It may be because
rom an all-cause mortality perspective, beyond transplantation
here is nothing to offer to these patients barring left ventricular
ssist devices, which is a field under investigation. Because of
he severe donor organ shortage, even if a patient with a
better” predicted outcome dies, it does not matter as much
ecause we are currently not able to save all of the “sicker” ones
nyway. Also, many of these patients will have a worsening
linical course over time and one can adjust their scores and
ence prediction of all-cause mortality.
Can we develop similar risk scores for SCD based on
ultiple patient characteristics and comorbidities that perform
s well? If not for SCD per se, then at least for predicting
hether a patient will benefit from a defibrillator? Of course
e can, and some investigators have attempted to do so (7).
owever, whether will they be accepted by the medical
rofession is not certain. A c-statistic of 0.75 or even 0.80
robably will not be good enough to change practice for an
ff-the-shelf technology such as a defibrillator, primarily be-
ause the degree of uncertainty and the level of acceptable risk
ave not been defined.
Should there be a standard of “low risk” when we should not
lace defibrillators? For better or for worse, the medical
ommunity has accepted the notion of cost effectiveness. Renal
eplacement therapy with dialysis is an accepted benchmark.
ny new therapy must stand the test of being in the ballpark
f dialysis with respect to cost effectiveness before it is widely
ccepted by the medical community. Should the medical
ommunity also develop some standards for the predictiveapabilities for tests and scores? Should there be acceptable risk
hresholds?
Prediction of the future is an inherent daily part of medical
ractice; however, no standards for an acceptable sensitivity
nd specificity of tests or predictive capabilities of prediction
ules are discussed. The details of doing this will be compli-
ated, but perhaps the time has come that it must be done.
his is not only applicable for defibrillators but also for many
ew diagnostic and therapeutic technologies. And one may
rgue that once we can define as a society what level and
ccuracy of prediction is acceptable to us and what risk is
olerable, and in turn we are legally protected by making those
ecisions, only then will we be able to practice more rational
edicine. If a test or a formula based on multiple patient
haracteristics puts a patient at 10% risk of SCD, should we
ot implant a defibrillator? Or should the threshold be 5%?
he question is not whether we can or cannot predict risk, the
uestion is what risk are we ready to tolerate? Until we answer
hese difficult questions, “everything for all” medicine is likely
o continue. The stakes are too high otherwise. But we must
ccept that this approach is unsustainable, and if the medical
ommunity does not take the lead to answer these important
uestions, government, regulators, payers, or someone else will!
Defibrillators do not stop the inevitable; they delay death,
ot prevent it. Delaying death may not always be for the best.
ot everyone with a defibrillator uses it, and not everyone who
ses it benefits from it. Patients with a defibrillator also die, as
oes everyone! In this light, the article by Goldenberg et al. (6)
n this issue of the Journal, although limited in scope, is a
elcome addition to this growing field, and the authors should
e commended for their effort.
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logy Division, Emory Crawford Long Hospital, MOT 6, 550
eachtree Road, Atlanta, Georgia 30308. E-mail: javed.butler@
moryhealthcare.org.
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